Clearbridge Investments LLC Sells 81,213 Shares of Relx Plc (NYSE:RELX)

Clearbridge Investments LLC cut its holdings in shares of Relx Plc (NYSE:RELX) by 3.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,151,851 shares of the technology company’s stock after selling 81,213 shares during the quarter. Clearbridge Investments LLC owned approximately 0.12% of Relx worth $97,737,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Thrivent Financial for Lutherans raised its holdings in shares of Relx by 83.0% in the 3rd quarter. Thrivent Financial for Lutherans now owns 10,665 shares of the technology company’s stock valued at $506,000 after purchasing an additional 4,836 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Relx by 13.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 120,300 shares of the technology company’s stock valued at $5,709,000 after buying an additional 14,088 shares during the period. Bank of Montreal Can lifted its position in shares of Relx by 194.9% in the third quarter. Bank of Montreal Can now owns 227,211 shares of the technology company’s stock valued at $10,806,000 after buying an additional 150,163 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Relx by 20.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 42,281 shares of the technology company’s stock worth $2,007,000 after acquiring an additional 7,239 shares during the period. Finally, Glenmede Trust Co. NA increased its holdings in shares of Relx by 2.9% during the 3rd quarter. Glenmede Trust Co. NA now owns 14,196 shares of the technology company’s stock worth $674,000 after acquiring an additional 405 shares during the last quarter. 15.02% of the stock is currently owned by institutional investors and hedge funds.

Relx Stock Up 0.5 %

Shares of NYSE RELX opened at $50.43 on Tuesday. The stock has a market capitalization of $93.61 billion, a P/E ratio of 27.12, a PEG ratio of 2.73 and a beta of 0.90. The stock’s fifty day moving average is $49.53 and its 200 day moving average is $47.84. Relx Plc has a 52 week low of $40.25 and a 52 week high of $51.99. The company has a debt-to-equity ratio of 1.46, a quick ratio of 0.47 and a current ratio of 0.52.

Relx Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Friday, May 9th will be given a $0.5586 dividend. The ex-dividend date of this dividend is Friday, May 9th. This is a boost from Relx’s previous semi-annual dividend of $0.23. This represents a dividend yield of 1.6%. Relx’s payout ratio is presently 59.68%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on RELX. Barclays raised shares of Relx from an “equal weight” rating to an “overweight” rating in a research report on Friday, March 14th. The Goldman Sachs Group assumed coverage on shares of Relx in a report on Wednesday, March 26th. They issued a “buy” rating on the stock. Redburn Atlantic started coverage on Relx in a research report on Wednesday, January 8th. They issued a “buy” rating on the stock. Finally, StockNews.com cut Relx from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Relx presently has an average rating of “Buy”.

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.